SG Americas Securities LLC Boosts Stock Position in GSK PLC Sponsored ADR (NYSE:GSK)

SG Americas Securities LLC boosted its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 71.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,840 shares of the pharmaceutical company's stock after purchasing an additional 7,849 shares during the quarter. SG Americas Securities LLC's holdings in GSK were worth $730,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Parkside Financial Bank & Trust lifted its position in shares of GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after buying an additional 818 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in GSK during the fourth quarter valued at $39,000. Bank Julius Baer & Co. Ltd Zurich purchased a new position in GSK during the fourth quarter valued at $40,000. Atala Financial Inc acquired a new stake in shares of GSK in the fourth quarter valued at about $45,000. Finally, Whipplewood Advisors LLC purchased a new stake in GSK during the 4th quarter worth approximately $46,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Trading Up 1.0%

GSK stock traded up $0.40 during trading on Tuesday, reaching $38.66. 4,820,942 shares of the stock were exchanged, compared to its average volume of 4,934,783. The business has a 50 day moving average price of $38.64 and a 200-day moving average price of $36.87. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $44.67. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21. The firm has a market capitalization of $79.14 billion, a price-to-earnings ratio of 19.93, a P/E/G ratio of 1.33 and a beta of 0.52.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. GSK had a return on equity of 48.82% and a net margin of 9.89%. The firm's quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.43 earnings per share. On average, research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be issued a $0.4216 dividend. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.36%. The ex-dividend date is Friday, May 16th. GSK's payout ratio is 87.11%.

Analyst Upgrades and Downgrades

GSK has been the topic of a number of research analyst reports. Wall Street Zen lowered GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Hsbc Global Res upgraded GSK to a "strong sell" rating in a report on Monday, April 28th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, BNP Paribas started coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price for the company. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.